Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

6
10 Dividend Stocks That Will Double Your Money

2018-07-16 investorplace
Is it possible to double your money – quickly – buying safe dividend stocks? You bet. Let me explain how…
EAT HTA TWX MAIN AWR TWC BPL MSCA.CL FRT T AOS MSCA VZ DOV FAF FRT.PRC MO

4
Factors That Are Likely to Impact Dover's (DOV) Q2 Earnings

2018-07-16 zacks
Earnings Whispers Our proven model cannot conclusively predict if Dover will beat the Zacks Consensus Estimate this time. That’s because it doesn’t have the right combination of two key ingredients — a positive Earnings ESP and a Zacks Rank #3 (Hold) or better — to increase the odds of an earnings beat.
NTRS GTT NTRSP DOV

17
The World Cup of Dividend Stocks: 8 of the Most Dependable Dividends

2018-07-16 investorplace
The World Cup began in 1930. After a 12-year break due to World War II, the soccer — oops, fútbol — tournament has been played every four years since 1950. This weekend we watched France beat Croatia 4-2 to win the 2018 World Cup. But it got us thinking, what about a World Cup for dividend stocks?
LOW PG PH AWR GPC NYTAB CL JNJ NWN KO DOV EMR MMM

46
10 Top 'Safer' Dividend Aristocrats Show 12.5-32.9% Gains Per July Audit

2018-07-12 seekingalpha
41 of 53 S&P 500 Dividend Aristocrats stocks were deemed "safer" for dividends because they showed positive one-year returns and free cash flow yields greater than their dividend yields 7/9/18.
GD KMB SWK PEP JNJ CINF CVX ITW DOV ABBV ABBV LEG MCD

58
Top 10 Of 53 Dividend Aristocrats Yield 3.4%-6.2% In July Update

2018-07-11 seekingalpha
The 53 Aristocrats stocks represent all 11 Morningstar sectors. Broker target top 10 net gains ranged from 12.8% to 20.6%.
APD XOM WBA KMB PEP JNJ CVX DOV ABBV CAH ED ABBV MCD

115
Oakmark Equity And Income Fund: Second Quarter 2018

2018-07-11 seekingalpha
The Equity and Income Fund earned 0.2% in the quarter, while the Lipper Balanced Fund Index, the Fund’s performance benchmark, gained 1.1%.
PM C.WSA DOV.WI NOV TEL CVS FNF BAC C.WS.B CHTR APY.WI GM.WS.A FNFV C.WS.A GM.WS.B GM.WS.C C.PRP DOV C.PRU GM ORCL C.PRS LBRDB BAC C C.PRL AAL C.PRJ C.PRK BHGE COMM MA ARNC C.PRG TWC LBRDK C.PRC BHI C.PRPCL CGBBW OCLCF JLL LBRDA FL APY GM.WSB UNH

36
Dover (DOV) Down to Strong Sell: Should You Dump the Stock?

2018-07-02 zacks
On Jun 30, Dover Corporation (DOV - Free Report) was downgraded to a Zacks Rank #5 (Strong Sell). The downgrade can be attributed to concerns regarding retail refrigeration business and cost woes. Going by the Zacks model, companies holding a Zacks Rank #5 have strong chances of underperforming the broader market. Also, Dover’s share price movement has not been much impressive. Over the past year, the company has underperformed the industry it belongs to.
WFC WFCNP ROP WFC.WS DOV.WI IEX WFC.PRL WFC.PRJ WFC.PRT WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN DOV WFC.PRY WFC.PRX WFC.PRW WFC.PRV GTLS

2
DOV / Dover Corp. 11-K

2018-06-27 sec.gov
Document
DOV

66
New Strong Sell Stocks for June 27th

2018-06-27 zacks
Banco Bradesco S.A. (BBD - Free Report) is a provider of banking and financial products. The Zacks Consensus Estimate for its current year earnings has been revised 4.7% downward over the last 60 days.
BRS ABX DOV.WI CERN DOV DY ICHR ABX

2
Over 60 Years Of Dividend Increases, A Big Spin-Off And Hope

2018-06-27 seekingalpha
Now that DOV has spun-off its oil & gas business (Apergy), it will show more stable returns.
APY.WI DOV APY

2
Dover: The Worst Performing Dividend Champion Of 2018

2018-06-25 seekingalpha
The stock has been the worst performing Dividend Champion of 2018, falling 28.1% year to date.
MGRC DOV APY

40
NYC Hedge Fund Managers Make Spinoff Conference A Win

2018-06-18 valuewalk
The Edge held the very first Spinoff conference in NYC on Wednesday, June 6 at the exclusive Penn Club on 44th St. to a packed room. With almost 100 nyc hedge fund managers, The Edge debated where, if any, Spinoffs make money. The event was non-profit, and all donations went to the Alzheimer’s Association. We are proud that, together, we raised $5,500. I was nervous, of course. How many times do I stand up in front of some of the smartest brains in the world? It was a great experience, and the thing I liked personally was that everyone was a winner.
CSC GD OLN DOV.WI DOV AXTA DXC.WI CC DXC

21
Iranian Oil Production Could Be About To Plunge

2018-06-08 oilprice
Nick Cunningham is a freelance writer on oil and gas, renewable energy, climate change, energy policy and geopolitics. He is based in Pittsburgh, PA.
FP HON GEC GE DOV.WI 500325 RELIANCE 98LQ HON RIGD HLPD DOV GNE RLNIY

102
10 Top 'Safer' Dividend Aristocrats Yield 3%-4%, With 14%-29% Gains Per June Audit

2018-06-07 seekingalpha
42 of 53 S&P 500 Dividend Aristocrats stocks were deemed "safer" for dividends because they showed positive one-year returns and free cash flow yields greater than their dividend yields.
GD KMB SWK PEP JNJ CINF CVX ITW DOV ABBV LEG ABBV

112
53 Dividend Aristocrats Yield .5% To 6.12% Per June Reckoning

2018-06-07 seekingalpha
"S&P 500® Dividend Aristocrats measure the performance S&P 500 companies that have increased dividends every year for the last 25 consecutive years."---us.spindices.com.
XOM WBA KMB PEP JNJ CVX DOV ABBV CAH ED ABBV LEG

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

14h - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

15h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to DOV / Dover Corp. on message board site Silicon Investor.

Breakthrough Company????? Endovasc ENDV Dover Corporation
Dov Pharmaceutical, Inc - DOVP Comdisco Ventures (CDOV)
Andover.Net (ANDN) ENDOVASC LIPOSOMAL (PGE-1) COATING FOR STENTS
DOVD endovascular Tech. (EVTI)
CUSIP: 260003108